以天然产品为基础开发治疗勃起功能障碍的药物:一种来自植物的分子候选物Tribulus terrestris被综合性In Silico研究确定
Riya Vishwakarma1, Abel John Koshy1, Haritha Kalath1
1Centre for Integrative Omics Data Science, Yenepoya (Deemed to be University), Mangalore, India.
Omics : a journal of integrative biology
|August 22, 2025
概括
这项研究选了Tribulus terrestris植物化学物质用于勃起功能障碍 (ED) 治疗. Diosgenin,dehydro显示出强大的固酶-5 (PDE5) 抑制潜力,为ED治疗提供了一个有前途的天然替代品.
科学领域:
- 药理学和药物发现
- 自然产品化学
- 计算生物学
背景情况:
- 传统的勃起功能障碍 (ED) 治疗,主要是代酶-5 (PDE5) 抑制剂,有相关的副作用.
- PDE5 是阴茎光滑肌功能中的关键酶,对勃起反应至关重要.
- 自然产品为开发具有潜在改善安全性特征的新型ED疗法提供了有希望的途径.
研究的目的:
- 通过in silico选,识别 Tribulus terrestris 中具有强大的代酶-5 (PDE5) 抑制活性的植物化学物质.
- 评估已识别的化合物与PDE5酶的结合亲和力和相互作用.
- 评估这些天然化合物的潜力,
主要方法:
- 对Tribulus terrestris植物化学物质进行选,以对抗化酶-5 (PDE5) 酶.
- 分子对接模拟以确定结合亲和度 (kcal/mol) 并分析蛋白质与配体的相互作用.
- 在有前途的候选药物的药理动力学和毒性评估中.
主要成果:
- 来自Tribulus terrestris的diosgenin,dehydro,ruscogenin和hecogenin对PDE5表现出显著的负性结合亲缘关系,超过了对照药西尔德纳菲尔.
- 迪奥斯基宁,脱水体表现出最高的结合亲和力 (-11.1 kcal/mol) 和有利的结合自由能量 (-19.99 ± 5.99 kcal/mol).
- 键和范德瓦尔斯相互作用是蛋白质配体复合体形成的关键;在中ADMET分析支持了它们的治疗潜力.
结论:
- 来自 Tribulus terrestris 的植物化学物质,特别是 diosgenin,dehydro,显示出作为选择性化酶-5 (PDE5) 抑制剂治疗勃起功能障碍 (ED) 的显著潜力.
- 这些天然化合物可能为现有的ED药物治疗提供更安全的替代品.
- 需要进一步的体外和体内研究来验证这些Tribulus terrestris衍生化合物的治疗效果和安全性.
相关概念视频
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
246
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
246
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K


